Dotan Center Announces Recipients of Three-Year Research Grants
Five innovative projects awarded three-year grants to advance hemato-oncology research
The Dotan Center for Hemato-Oncology Research is pleased to announce the recipients of its latest three-year research grants.
A total of 18 high-quality proposals were submitted by researchers and physicians from Tel Aviv University and affiliated medical centers, reflecting the breadth and excellence of hemato-oncology research across the university and its clinical partners. Following a highly competitive review process, five outstanding projects were selected for funding.
The selected projects will receive grants of NIS 225,000 per year for up to three years, subject to research progress and the achievement of scientific milestones.
On behalf of all applicants, awardees, and committee members, we would like to express our sincere gratitude to the Dotan family for their ongoing support, commitment, and professional guidance, which have contributed significantly to the center’s activities and growth over the years.
Awardees
Research Grants (Three-Year Awards):
- Dr. Adi Zoref-Lorenz and Prof. Asaf Madi (Meir Medical Center and Gray Faculty of Medical & Health Sciences, TAU), in collaboration with Prof. Ofir Wolach - "Redefining Hyperinflammation in AML/MDS: a Biologically Distinct Disease State".
- Prof. Dinorah Friedmann-Morvinski and Prof. Michal Besser (George S. Wise Faculty of Life Sciences, TAU and Rabin Medical Center) - "p32/C1qbp as a Novel Target for Immunotherapy in Hematological Malignancies".
- Prof. Elad Jacoby (Sheba Medical Center and Gray Faculty of Medical & Health Sciences, TAU), in collaboration with Prof. Uri Ben-David - "Mechanisms of Resistance to CAR T-cells in Acute Lymphoblastic Leukemia Harboring TP53 Alterations".
- Prof. Ron Ram and Dr. Miri Neeman (Tel Aviv Sourasky Medical Center) - "Multimodal Epigenetic Blood Test for AML Subtyping and Treatment Response Prediction".
- Prof. Yair Herishanu and Dr. Ben Zion Katz (Tel Aviv Sourasky Medical Center) - "Targeting PTPN2 to Restore T-Cell Function and Potentiate Cellular Immunotherapies in Chronic Lymphocytic Leukemia".
We warmly congratulate the awardees, whose research proposals stood out for their quality, innovation, and potential to advance scientific discovery and clinical care in hemato-oncology.
Related Articles
